Preoperative phenotypic stratification of primary central nervous system lymphoma using multiparametric MRI-based radiomics: prediction of germinal center B-cell-like and double-expression status - Report - MDSpire

Preoperative phenotypic stratification of primary central nervous system lymphoma using multiparametric MRI-based radiomics: prediction of germinal center B-cell-like and double-expression status

  • By

  • Lingxu Chen

  • Xiaochen Wang

  • Sihui Wang

  • Tong Chen

  • Xuening Zhao

  • Ying Yan

  • Mengyuan Yuan

  • Shengjun Sun

  • June 29, 2026

  • 0 min

Share

Clinical Report: Preoperative Classification of Primary CNS Lymphoma Phenotypes

Overview

This study developed multiparametric MRI-based radiomics models for preoperative prediction of double-expression lymphoma (DEL) and germinal center B-cell-like (GCB) status in primary central nervous system lymphoma (PCNSL). The models demonstrated AUC values of 0.807 for DEL and 0.897 for GCB classification.

Background

Primary central nervous system lymphoma (PCNSL) is a rare but aggressive form of non-Hodgkin lymphoma confined to the central nervous system. Understanding the biological heterogeneity of PCNSL, particularly between DEL and GCB phenotypes, is crucial for treatment stratification. Noninvasive imaging techniques, such as MRI, may provide insights into tumor characteristics.

Data Highlights

ClassificationAUCAccuracySensitivitySpecificity
DEL0.807 (95% CI, 0.649–0.936)0.7300.7140.750
GCB0.897 (95% CI, 0.796–0.973)0.8460.7920.893

Key Findings

  • Multiparametric MRI sequences were utilized to analyze 160 pathologically confirmed PCNSL patients.
  • For DEL classification, 12 radiomic features were identified, with the SVM classifier achieving an AUC of 0.807.
  • For GCB classification, 7 radiomic features were used, with the Random Forest classifier achieving an AUC of 0.897.
  • The study highlights the use of MRI-derived radiomic features in capturing biological heterogeneity in PCNSL.

Clinical Implications

Multiparametric MRI-based radiomics can aid in the prediction of PCNSL phenotypes.

Conclusion

Multiparametric MRI-based radiomics shows potential for the classification of PCNSL phenotypes.

Related Resources & Content

  1. Understanding Delays in Diagnosis and Treatment of Primary Central Nervous System Lymphoma: Insights for Neurosurgeons, Springer, 2024 -- Understanding Delays in Diagnosis and Treatment of Primary Central Nervous System Lymphoma: Insights for Neurosurgeons
  2. Blood Cancer Journal, 2025 -- Macrophages Expressing PDL1 Infiltrate Diffuse Large B-Cell Lymphoma and Enhance Tumor Growth in a MYC-Driven Experimental Model
  3. Journal of Neuro-Oncology, 2025 -- MRI Characteristics of CNS Large B-cell Lymphoma: An Analysis of Susceptibility and T2*-weighted Imaging in a Large Cohort from a Single Center
  4. Primary CNS Lymphoma Treatment (PDQ®) - NCI, NCI -- Primary CNS Lymphoma Treatment (PDQ®)
  5. Blood Cancer Journal — Characterization of Spatial Phenotypes in Nodular Lymphocyte Predominant Hodgkin Lymphoma and T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
  6. Primary CNS Lymphoma Treatment (PDQ®) - NCI
  7. The Landscape of Primary Central Nervous System Lymphoma (PCNSL): Clinicopathologic and Genomic Characteristics and Therapeutic Perspectives
  8. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up - PMC
  9. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial | Leukemia
  10. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) - PMC
  11. Multiparametric MRI-Based Radiomics for Identifying Primary Central Nervous System Diffuse Large B-cell Lymphomas’ Pathological Subtypes - ScienceDirect
  12. Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma - PubMed

Original Source(s)

Related Content